Define Ventures
Define Ventures is an early-stage firm focused on health technology and the modernization of healthcare.
- Healthcare and biotechnology venture capital investor
- Healthcare & BioTech Venture Capital
- Tier III
Overview
Define Ventures is an early-stage firm focused on health technology and the modernization of healthcare. It invests in software, data, care-delivery, payer, provider, consumer-health, and clinical platforms rather than concentrating on drug development.
Its team combines venture experience with healthcare operating knowledge and relationships across health systems, insurers, employers, and technology companies. That network can help founders refine market positioning, recruit leaders, build strategic partnerships, and secure follow-on capital. Within The Economy Wiki, the institution is connected to the Healthcare & Biotechnology Venture Capital market category.
Firm facts
| Institution | Define Ventures |
| Type | Healthcare and biotechnology venture capital investor |
| Headquarters | San Francisco, United States |
| Founded | 2019 |
| Primary ranking focus | Healthcare & BioTech Venture Capital |
| Highest 2026 tier | Tier III |
Activities and investment capabilities
Define Ventures operates within life-sciences innovation, clinical development and healthcare company building. Its category-specific capabilities are summarized below.
Life-sciences investing
Capital for therapeutics, diagnostics, medical devices and research platforms.
Clinical development
Support across scientific validation, trials, regulation and commercialization.
Healthcare innovation
Investment in care delivery, health technology and data-enabled medical businesses.
Strategy and market coverage
Stage and strategy coverage
Company formation through growth; translational research; clinical and commercial financing
Sector and market coverage
Biotechnology; therapeutics; diagnostics; medtech; digital health and healthcare services
Market position
Define fits Tier III because it is younger than the long-established life-sciences firms, but its focused healthtech mandate, institutional fund scale, operating expertise, and strong communications platform make it one of the category’s more relevant emerging specialists.
Define Ventures is assessed within the Healthcare & Biotechnology Venture Capital framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
Define Ventures is recognized Tier III in Top 30 Healthcare & BioTech Venture Capital 2026. The rankings compare institutions by market relevance, investment or operating capability, sector and stage expertise, institutional credibility and current activity. Comparable links support navigation and do not imply that every institution competes for every company, fund commitment or transaction.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through the institution’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to Define Ventures as the public-facing organization. Individual funds, management companies, advisers, lending entities, broker-dealers and regulated affiliates may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | Define Ventures |
| Headquarters | San Francisco, United States |
| Public website | www.definevc.com |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the venture, financing, diligence and private-market themes relevant to this institution:
- The Mid-Market Advantage in Healthcare Private Equity
- Growth Equity vs Venture Capital and Buyouts: Key Differences
- Private Equity Technology Due Diligence in the AI Era
